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Fig. 1. Clinical and histopathological features of psoriasis. (A) 
Isolated or confluent sharply demarcated erythematous scaly pla-
ques are typical cutaneous manifestations for chronic psoriasis. (B) 
Hyperplastic epidermis and a large number of skin-infiltrating in-
flammatory cells accompanying increased vasculatures are histo-
pathological characteristics of chronic psoriatic lesions.
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Psoriasis is a chronic inflammatory disorder characterized by 
an erythematous scaly plaque of the skin and is occasionally 
accompanied by systemic complications. In the psoriatic 
lesions, an increased number of cytokine-producing dendritic 
cells and activated T cells are observed, which indicate that 
psoriasis is a prototype of an immune-mediated dermatosis. 
During the last decade, emerging studies demonstrate novel 
roles for the dendritic cell subsets in the process of disease 
initiation and maintenance of psoriasis. In addition, recently 
discovered anti-psoriatic therapies, which specifically target 
inflammatory cytokines produced by lesional dendritic cells, 
bring much better clinical improvement compared to 
conventional treatments. These new therapies implicate the 
crucial importance of dendritic cells in psoriasis pathogenesis. 
This review will summarize and discuss the dendritic cell 
subsets of the human skin and their pathophysiological 
involvement in psoriasis based on mouse- and patient-oriented 
studies. [BMB Reports 2014; 47(2): 60-68]
INTRODUCTION
Psoriasis is a chronic inflammatory disease of the skin that af-
fects 1-2% of the global population (1). Its occurrence is more 
common in the Western population compared to Asian, and 
clinical presentations are different among the races, which em-
phasize the important roles for genetic and environmental fac-
tors in psoriasis pathogenesis (2-4). Psoriasis primarily involves 
the skin; however, it could occasionally affect the articular 
joints (psoriatic arthritis), which leads to a disabled joint 
motility. The chronic nature of the psoriatic inflammation 
could be complicated with systemic inflammatory status (5). 
Patients with severe psoriasis are associated with a greater risk 
for systemic comorbidities, including cardiovascular diseases 
and metabolic syndrome, suggesting that psoriasis is a sys-
temic inflammatory disorder, rather than a sole skin disease (6, 
7). Furthermore, psoriatic patients suffer from both physical 
and psychological distress during social work, due to their 
characteristic cutaneous marks (8). Thus, continuous efforts to 
develop the optimal treatment options against psoriasis are tru-
ly needed to increase the quality of life outcomes of the 
patients.
　Psoriatic lesions are characterized by thick and eryth-
ematous non-pruritic plaques covered by silvery scale on the 
skin, which could be differentiated from other eczematous in-
flammatory diseases, such as atopic dermatitis or contact der-
matitis (Fig. 1A). Under the microscopic examination, psoriatic 
plaques reveal a set of typical histological features, including 
hyperproliferation of keratinocytes in the epidermis (acantho-
sis) and a huge number of skin-infiltrated inflammatory cells 
mainly found in the dermis with accompanying increased vas-
culatures (Fig. 1B). Those cellular infiltrates are comprised of 
dendritic cells (DCs), macrophages, and T cells. In addition, 
one can easily detect a group of neutrophils (Munro’s micro-
abscess) and scattered T lymphocytes in the epidermal com-
partment (4). Because psoriatic lesions contain a markedly in-
creased number of inflammatory cells, it has been postulated 
that psoriasis is a disease caused by an altered immune system 
of the body (4, 9). Initial studies have focused on the role of T 
lymphocytes in the pathogenesis of psoriasis because a huge 
number of T cells are infiltrated in the psoriatic lesions, and 
the use of calcineurin inhibitors or agents targeting T cells 
leads to clinical improvement which has demonstrated the cru-
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cial pathogenic role for T cells (10). Among the T cells, 
IFN-γ-producing T cells had been specifically investigated by 
researchers, because the psoriatic skins characteristically ex-
press type 1 immune signatures, compared to atopic dermatitis 
skins which are associated with an increased type 2 immune 
molecules (11, 12). However, recent clinical and genome-ori-
ented, population-based studies have elucidated the chief in-
volvement of IL-17A-producing helper T cells (Th17) in the 
pathogenesis of psoriasis (13, 14). IL-17A could activate epi-
dermal keratinocytes or other epithelial cells to produce the in-
flammatory molecules that mediate Th17-associated inflam-
mations (15-17). Psoriatic lesions exhibit a highly elevated 
Il17a message level, and lesion-infiltrating T cells actively pro-
duce IL-17 cytokine upon in vitro stimulation (18, 19). More 
importantly, emerging clinical trials have shown a good ther-
apeutic efficacy for the use of anti-IL-17A or anti-IL-17 recep-
tor. A monoclonal antibodies in the treatment of severe psor-
iasis, which also emphasizes the pivotal involvement of IL- 
17A-producing T cells in psoriasis (20, 21). Although lesional 
T cells present an activated and memory phenotype in situ, the 
cellular mechanisms for controlling their pathologic activation 
so far remain elusive (22, 23). Thus, it would be noteworthy to 
clarify the upstream cellular sources or molecules that partic-
ipate in the process of T cell activation for the development of 
new therapeutic modalities for psoriasis treatment.
　DCs are bone-marrow-derived, professional antigen-present-
ing leukocytes that link innate and adaptive immunity (24). 
They finely orchestrate the magnitude and direction of adap-
tive immune responses against pathogens, via priming and ac-
tivating T lymphocytes according to the particular environ-
mental circumstances (25). DCs are composed of heteroge-
neous subsets classified by surface markers, anatomical loca-
tions, and functional specificities. DCs are found in the blood, 
lymphoid tissues, and almost all peripheral organs, including 
skin, which implicate the important position of DCs in im-
mune surveillance (26). Owing to their distinctive ability to 
regulate T cell immune responses, DCs have long been recog-
nized as playing a central role for the development of multiple 
inflammatory disorders, such as psoriasis (25). Recent ad-
vances have provided a bunch of evidence that DCs actively 
participate in the pathogenesis of psoriatic inflammation (27). 
The aim of this review is to present a recent understanding of 
the DC network in the normal human skin, and how cuta-
neous DCs play a role in the pathogenesis of psoriasis to pro-
vide the concept that DCs are promising therapeutic target for 
anti-psoriasis treatment.
DC SUBSETS IN THE NORMAL HUMAN SKIN
Heterogeneous DC populations are located in the quiescent 
human skin. Although much effort has been conducted to clar-
ify the precise taxonomy for cutaneous DCs, the current classi-
fication for DC subsets in the skin is still somewhat compli-
cated, due to a great number of surface antigens to be used for 
identifying DCs and functional modification during the tissue 
preparation for ex vivo experiments. Nevertheless, recent ele-
gant studies have established the discrete resident subsets of 
DCs in the steady-state human skin: 1) epidermal Langerhans 
cells (LCs), 2) dermal myeloid DCs (mDCs), and 3) plasmacy-
toid DCs (pDCs) (28, 29).
　LCs are distinct subset of DCs that reside in the suprabasal 
epidermis where they organize a lacelike network (30). LCs 
are characterized by the expression of C-type lectin Langerin 
(CD207) and a major histocompatibility complex I-like mole-
cule CD1a, which could act as molecular receptors that recog-
nize and endocytose carbohydrate structures of the pathogens 
and microbial lipids, respectively (31). LCs have a unique in-
tracellular ultrastructure called Birbeck granule, visible by 
electron microscope, which is associated with the internalized 
Langerin (32, 33). The homeostasis of LCs differ from that of 
other DC subsets, in that LCs are believed to sustain their epi-
dermal pool by self-renewal throughout the life (34). The role 
of LCs in cutaneous immunity has not been conclusive so far 
(30). Currently, we have understood that LCs represent bidirec-
tional functions in cutaneous immune responses in different 
contexts (i.e. immune-stimulatory or immune-regulatory) that 
have still been a matter of controversy (35). Recently it has 
been shown that LCs could induce IL-22 production by a sub-
set of CD1a-autoreactive T cells through CD1a molecule to 
support the epithelial immunologic barrier of the skin (36, 37). 
Seneschal et al. reported sophisticated study that LCs are basi-
cally programmed to primarily induce the proliferation of skin 
resident regulatory T cells; however, foreign pathogen-acti-
vated LCs have converted their characteristics to activate and 
proliferate skin resident effector memory T cells, suggesting 
the dual role for LCs in cutaneous immunity depending on the 
presence or absence of infectious challenge (38).
　Dermal mDCs are a classic type of DCs that are mainly lo-
cated in the upper part of the dermis (28, 39). The best surface 
antigen known for the identification of dermal mDCs is a mye-
loid marker CD11c. Historically, dermal mDCs had been 
called “dermal dendrocytes” according to their dendritic 
appearance. Early studies had recognized dermal dendrocytes 
by the expression of Factor XIIIA antigen (40, 41). However, 
recent double immunofluorescence-based in situ study has 
clearly shown that most CD11c+ dermal mDCs characteristi-
cally co-express CD1c (BDCA-1) but not Factor XIIIA, while 
the positivity for Factor XIIIA denotes another cellular pop-
ulation, namely, dermal macrophages (39). Purified CD1c+ 
mDCs show a relatively immature phenotype with poor im-
munostimulatory activity; however, the addition of maturation 
stimuli for DCs greatly increases their ability to induce T cell 
proliferation (39). CD1c+ dermal mDCs are shown to have a 
capacity for priming and activating CD4+ T cells ex vivo; how-
ever, the amount and direction of T cell responses mounted by 
dermal mDCs has been reported to be somewhat discrepant 
among the research groups, possibly depending on the mDC 
isolation techniques (42-45).
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Fig. 2. A schematic model for the central role of dendritic cell 
(DC) subsets in psoriasis. Psoriatic plasmacytoid DCs (pDCs) pro-
duce type I interferon, including IFN-α, and participate in the ini-
tiation phase of psoriatic inflammation. TNF-α- and inducible ni-
tric oxide synthase-producing DCs (Tip-DCs) are inflammatory DC 
subset found in the psoriatic skins. They actively produce proin-
flammatory molecules, TNF-α and iNOS, to enhance the psoriatic 
inflammation. IL-12 and IL-23 are also expressed by Tip-DCs, and 
are crucial for Th1 and Th17 development and expansion, 
respectively. Th17-driven IL-17A and IL-22 act on keratinocytes to 
induce CC chemokine 20 (CCL20) and anti-microbial peptides. 
Highly increased epidermal CCL20 attracts CCR6-bearing Th17 
cells, and recruited Th17 cells further activate keratinocytes to 
produce CCL20 in a positive feedback manner. Lesional self-RNA 
and anti-microbial peptide LL-37 could be combined to generate 
self-RNA/LL-37 complex, which activates resident immature DCs 
to be mature DCs (DC-LAMP+). Those DC-LAMP+ mature DCs 
frequently aggregate with lesional T cells possibly via certain che-
mokine systems, including CCL19/CCR7 or CCL20/CCR6.
　There is another population of dermal mDCs recognized by 
the expression of CD141 (BDCA-3) in the normal human skin, 
comprising a relatively small fraction of mDCs (approximately 
10%) (28, 39, 46). These CD141+ mDCs have initially been 
identified in the blood, and shown to be less im-
munostimulatory compared to CD1c+ mDC subset (47). 
Recent investigations on CD141+ human mDCs have pro-
vided the evidence for the important role of CD141+ mDCs in 
cross-presenting exogenous antigens to CD8+ T cells, a proc-
ess that is crucial for anti-viral, anti-tumoral, and vaccination 
immunity (48-50). In the mouse system, CD8α+ DC subset 
possesses cross-presenting ability, which represents mouse 
CD8α+ DCs as a counterpart to human CD141+ mDCs (51). 
Human CD141+ mDCs are also characterized by CLEC9A and 
XCR1 expression discovered by recent comparative biology 
approaches (52, 53). Haniffa et al. have recently explored a 
wide range of human peripheral tissue CD141+ mDCs which 
harbor cross-presenting ability with functional similarity to 
mouse CD103+ nonlymphoid DCs (46). These results indicate 
that human peripheral CD141+ mDCs could be a promising 
target for mounting vaccination immunity against viral in-
fections or multiple tumors through the relatively simple pe-
ripheral routes, including skin.
　pDCs are a unique DC subset initially described by their 
similar morphology with plasma cells (54). Immunophenotypi-
cally, pDCs are distinguishable from classic mDCs by their 
lack of myeloid markers CD11c or CD11b, while expressing 
CD123, CD303 (BDCA-2), and CD304 (BDCA-4) (55). They 
are generally poor stimulators for T cell priming and activation 
compared to mDCs; however, pDCs are specifically equipped 
for rapidly producing type I interferon in response to toll-like 
receptor 7 (TLR7) or TLR9 engagement by viral or self-nucleic 
acids (55, 56). This particular characteristic designates pDCs as 
a central defender against viral infections. Recent evidences 
have suggested that pDCs located in peripheral tissues are di-
rectly associated with the induction of tolerance via regulating 
regulatory T cells, indicating that pDCs actually play a dual 
role for immune responses depending on the circumstances 
(57). In the normal human skin, pDCs are rarely detectable 
and their precise function remains to be determined (39, 58).
DC SUBSETS IN THE PSORIATIC SKIN AND THEIR ROLE 
FOR PSORIASIS PATHOGENESIS
Psoriatic skin contains a highly increased number of CD11c+ 
mDCs in the dermis, suggesting the important role of mDCs in 
the psoriasis pathogenesis (59) (Fig. 2). Psoriatic mDCs are 
comprised of both immature and mature phenotypes, and ma-
ture mDCs are characterized by dendritic cell-lysosomal-asso-
ciated membrane protein (DC-LAMP) or CD83 expression. 
Typically, those mature mDCs present as dense cellular clus-
ters, frequently aggregated with lesional infiltrating T cells, 
which resemble the lymphoid-clusters of secondary lymphoid 
organs or inflamed peripheral tissues (59-62). Because a ma-
jority of lesional-infiltrating T lymphocytes present proliferat-
ing status and activated memory phenotype, it has been postu-
lated that cluster-forming mature mDCs could act as the cel-
lular nidus, which contribute to the disease progression by au-
toantigen presentation and activation of T cells in situ (22, 23, 
63-65). Thus, the way for inhibiting T cell activation via inter-
fering with DC/T cell interaction has been considered to be an 
effective therapeutic strategy for psoriasis. Currently, two bio-
logical regimens have been assessed to repress psoriatic in-
flammation by targeting co-stimulatory activating signals on T 
cells generated by cellular contact with antigen-presenting 
DCs. Alefacept is a human lymphocyte function-associated an-
tigen-3 (LFA-3) fusion protein that binds to CD2 molecules, 
and it blocks the interaction between co-stimulatory molecule 
LFA-3 and CD2 expressed on DCs and T cells, respectively (9, 
66). The administration of alefacept in psoriatic patients re-
vealed a good clinical therapeutic efficacy, accompanied with 
the decreased number of lesion-infiltrating DCs and T cells 
(59, 67, 68). Efalizumab is a chimeric monoclonal anti-CD11a 
(alpha chain of LFA-1) antibody that blocks LFA-1 of T cells, 
the molecule that binds with intercellular adhesion molecule 1 
(ICAM-1) expressed by endothelial cells and DCs (9). It inhibits 
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the cell-to-cell adhesion between T cells and DCs thereby re-
ducing the T cell activation (69). Although efalizumab has 
been withdrawn from the market due to its severe side effect, 
initial clinical studies using efalizumab revealed a good ther-
apeutic effect on the treatment of psoriasis (70).
　Chemokine systems play a central role for tissue trafficking 
of diverse leukocytes, including DCs and T cells (71). 
Although a number of chemokine pairs are expressed in the 
psoriatic plaques (72, 73), the precise chemokines that contrib-
ute to the recruitment and formation of dermal DC/T cell clus-
ters have been poorly understood yet. Mitsui et al. have re-
ported that dermal clusters of the psoriatic skin express lym-
phoid-organizing CCL19 ligand and its receptor CCR7 (74). 
Apart from the results by Mitsui et al., we have recently dem-
onstrated in situ evidence for the association of CCL20/CCR6 
chemokine system with psoriatic dermal aggregates (75). 
Lesional aggregating DC-LAMP+ mature mDCs and T cells ex-
pressed CCR6 and, interestingly, psoriatic DCs and T cells 
were the prominent cellular sources for CCR6 ligand, CCL20. 
Importantly, the number of dermal DC-LAMP+ mature DCs 
was significantly higher in chronic psoriasis compared to other 
acute inflammatory skin lesions, and correlated to disease se-
verity, indicating possible pathologic involvement of mature 
mDCs in the chronic nature of psoriasis. In line with our data, 
Ganguly et al. reported that self-RNA/LL-37 complexes were 
able to activate mDCs via TLR8-dependent manner, and the 
positive correlation between DC-LAMP+ mature mDCs and 
the amount of lesional self-RNA/LL-37 complexes was ob-
served in chronic psoriatic plaques (76). Thus, a blockade of 
the formation of dermal DC/T cell immunological aggregates 
may be a promising therapeutic target for alleviating chronic 
psoriasis, especially via targeting specific chemokine pairs, in-
cluding CCL19/CCR7 and CCL20/CCR6.
　The composition of DC subsets found in the psoriatic pla-
ques is quite different from those in cases of quiescent skin. 
Emerging studies have allowed us to understand the re-estab-
lished DC network present in the psoriasis and their pathologic 
engagement with psoriatic inflammation (27). 
pDCs as an initiator of the psoriatic inflammation
In contrast to normal skin, an increased number of pDCs was 
detected in psoriatic skin (77, 78). Clinically, topical applica-
tion of TLR7 agonist imiquimod aggravated psoriasis, with in-
creased number of pDCs in the dermal infiltrating cells (78). 
These findings were in accordance with a previous study, 
which revealed an evident IFN-α signature in psoriatic skin le-
sions (79). In addition, during the last decade, decent studies 
have shown a role for pDCs during the initiation phase of 
psoriasis. Nestle et al., with their xenograft mouse model of 
human psoriasis, demonstrated that the development of psor-
iasis can be prevented by blocking IFN-α. Furthermore, se-
quential analysis of psoriasis development in xenograft model 
revealed that IFN-α signaling signature is actually present in 
developing psoriasis, and precedes the characteristic psoriatic 
phenotype (79-81). However, the exact mechanism of pDCs 
activation in psoriatic skin remained unknown. Subsequent el-
egant studies had shown that the cathelicidin LL-37, which is 
upregulated endogenous antimicrobial peptide in psoriatic 
skin, binds to self-DNA and self-RNA released from stressed or 
dying cells and activates pDCs via TLR9 and TLR7, re-
spectively, and induces type I IFN production (76, 80). Since 
pDCs are tolerant to self-DNA/RNA during homeostasis, LL-37 
is necessary to break this innate tolerance. Therefore, LL-37 
mediates recognition of self-DNA and self-RNA, probably re-
leased from injured or stressed epidermal cells, by pDCs, and 
activates them to initiate psoriasis development. However, the 
exact source and characteristics of self-DNA/RNA in psoriasis 
are not fully identified. Moreover, whether pDCs from psor-
iasis patient are more prone to LL-37 mediated activation 
needs to be studied in the near future.
TNF-α and inducible nitric oxide synthase (iNOS)-producing 
myeloid DCs are pathologic inflammatory DCs in psoriasis
As mentioned above, a markedly increased number of 
CD11c+ mDCs is observed in the psoriatic dermis (∼30 times 
higher compared to the normal skin) (28, 59, 82). An initial 
functional study conducted by Nestle et al. showed that psori-
atic dermal DCs are capable of stimulating autologous T cells, 
with the induction of IL-2 and IFN-γ cytokine production (65). 
Because psoriatic skin expressed high level of iNOS and 
TNF-α, which are potent inflammatory mediators (83, 84), 
Lowes et al. investigated the in situ local expression of those 
molecules in the psoriatic plaques. Notably, CD11c+ mDCs 
are unique cellular sources for iNOS and TNF-α in psoriatic 
dermis (59). Previously TNF-α- and iNOS-producing DC subset 
(called Tip-DCs) have been identified in the spleens of Listeria 
monocytogenes-infected mice, and they play a crucial role for 
eradicating intracellular Listeria (85). Interestingly, these 
Tip-DCs-like mDC subsets have been found in the human 
psoriatic dermis by Lowes et al., and an initial large scale clin-
ical study showed that a blockade of TNF-α using etanercept 
led to a significant reduction in the severity of psoriasis (86). 
These results indicate that TNF-α cytokine-producing in-
flammatory mDCs are critically involved in the pathogenesis 
of psoriasis. Moreover, local gene expression profiles within 
psoriatic skins before and after treatment with etanercept re-
vealed that TNF-α suppression was significantly associated 
with the downregulation of Th17-associated genes, and eta-
nercept-treated in vitro-generated DCs were poor stimulators 
for T cell proliferation responses, indicating that TNF-α directly 
regulates DC functions in an autocrine and/or paracrine man-
ner (60). In addition to etanercept, other TNF-α-blocking bio-
logic agents, such as adalimumab and infliximab, have been 
shown to have a significant therapeutic effect for alleviating 
psoriasis (87). IL-23 is a key cytokine that promotes the ex-
pansion of the IL-17-producing Th17 cells (88). DCs are 
known as one of the cellular sources for IL-23 production, and 
IL-12/23p40 and IL-23p19 mRNA were highly expressed in the 
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psoriatic skins (60). In the mouse study, intradermal injection 
of IL-23 induced a Th17-dependent psoriasis-like cutaneous in-
flammation (89, 90). Psoriatic mDCs have been demonstrated 
to produce IL-23, and functionally they were capable of pro-
liferating and activating CD4+ T cells to produce IL-17A upon 
mixed leukocyte reactions (18, 82, 91, 92). Those mouse- and 
human-based studies essentially implicate the crucial role of 
IL-23 in the pathogenesis of psoriasis. Ustekinumab is an an-
ti-IL-12p40 monoclonal antibody that binds to the p40 subunit 
of human IL-12 and IL-23, and prevents its interaction with 
IL-12Rβ1 (9, 93). The use of ustekinumab shows a significant 
efficacy for the treatment of psoriasis, and was recently ap-
proved by the FDA for biological therapeutics for psoriasis 
(94-96). Collectively, cytokine-producing mDCs of psoriasis 
are a central target for anti-psoriatic strategies, and recent clin-
ical trials have provided a new avenue for the psoriasis 
treatments.
　Although the phenotypic characteristics and functional prop-
erties of the psoriatic inflammatory mDCs have been ex-
tensively investigated, their precise cellular origins have not 
yet been elucidated. Zaba et al. have reported that those in-
flammatory Tip-DCs in the psoriatic dermis express CD11c 
myeloid marker, but are devoid of CD1c, that is, Tip-DCs are 
phenotypically CD11c+CD1c- (82). This result indicates that 
psoriatic inflammatory DCs are different from CD1c+ resident 
dermal mDCs, in part due to a differential surface antigens 
expression. Zaba et al. also showed that TNF-related apopto-
sis-inducing ligand (TRAIL) was a marker for CD11c+CD1c- in-
flammatory DCs, distinguishing them from CD1c+ resident 
mDCs identified using a transcriptome-based approach (97). 
However, principal component analysis revealed the close ge-
nomic similarity between psoriatic CD1c- inflammatory and 
CD1c+ resident DCs, suggesting the possible progression of 
psoriatic inflammatory DCs from the skin-resident or 
blood-driven CD1c+ mDCs. Some researchers have demon-
strated that 6-sulfo LacNAc DCs (slanDCs) are prominent cel-
lular sources for TNF-α, iNOS, and IL-23 in the psoriatic der-
mis, and could induce the production of IL-17A from the 
CD4+ T cells after DC/T cell co-culture (98). In addition, treat-
ment with anti-TNF-α antagonist infliximab led to the down-
regulation of proinflammatory cytokines produced by slanDCs 
and suppressed their T cell-activating ability, indicating that 
slanDCs are a promising cellular target for anti-TNF-α thera-
pies (99). Although the surface phenotype of slanDCs is similar 
to those of inflammatory DCs of psoriasis (i.e. CD11c+CD1c-), 
they characteristically express CD16, which is also detected 
on the human non-classical monocytes subsets (100). In addi-
tion, gene expression of CD16+ monocytes is comparable to 
mouse Gr-1 low monocytes, suggesting that CD16+ cells, in-
cluding slanDCs, are actually monocytes rather than DCs 
(101). Thus, further investigations are needed to shed light on 
the cellular identity of the psoriatic inflammatory DCs.
LCs: a bystander?
Currently, the exact role of LCs in the pathogenesis of psoriatic 
inflammation has not been elucidated. Although the cellular 
number and morphology of LCs were comparable between the 
uninvolved skin of psoriasis and normal skin of healthy sub-
jects, LCs residing in the uninvolved skin of the psoriatic pa-
tients revealed a defective migratory property in response to 
the various LC mobilization-inducing stimuli, including intra-
dermal injection of IL-1β or TNF-α (102). Interestingly, accord-
ing to the ages of onset for psoriasis, LCs in the uninvolved 
skin of early-onset psoriasis could respond to IL-1β; but those 
of late-onset psoriasis could not, indicating the important dif-
ferences in LC function between early- and late-onset psoriasis 
(103). However, functional relevance for the migratory defects 
in psoriatic LCs remains to be determined.
CONCLUSION
Emerging studies have established the cutaneous DC networks, 
and highlighted their specific role for the skin immune 
homeostasis. Furthermore, there are expanding evidence re-
garding the pathophysiological role of cutaneous DC subsets 
in the psoriasis pathogenesis clarified by the recent elegant 
efforts. It is now clear that cutaneous DCs are specifically in-
volved in the cascade of psoriatic inflammation, and they are 
attractive targets for the current psoriasis treatment. Future 
studies should focus on the elucidation of cellular origin, re-
cruitment mechanisms, and other uncharacterized functions of 
the DC subsets present in psoriasis to develop new therapeutic 
modalities against chronic psoriasis. 
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